PubMed Health⌕ Search

PubMed · 11782143

Molybdenum complexes with linked cycloheptatrienyl-phenolate ligands.

Abstract

The tropylium salt (2-hydroxy-3,5-dimethylphenyl)cycloheptatrienylium tetrafluoroborate (3) has been synthesized in three steps from THP-protected 2,4-dimethylphenol and tropylium tetrafluoroborate, (C(7)H(7))BF(4). In CH(2)Cl(2) solution, the unexpected formation of tricyclic 2,4-dimethylbenzo[b]cyclohepta[d]furanylium tetrafluoroborate (5) has been observed, which must have formed from 3 by loss of H(2). 5 was characterized by an X-ray crystal structure determination and could independently be synthesized by treatment of 3 with NaHCO(3) to give 2,4-dimethylbenzo[b]cyclohepta[d]furan (4) followed by acidification with HBF(4).Et(2)O. The arene transfer reaction of 3 with [(eta-p-xylene)Mo(CO)(3)] furnished the cycloheptatrienyl complex [(HOC(6)H(2)Me(2)-eta(7)-C(7)H(6))Mo(CO)(3)]BF(4) (6), which could be converted into the chiral chelate complexes [(OC6H2Me2-eta7-C7H6)Mo(CO)(PR3)](9a, R = Ph; 9b, R = c-C(6)H(11); 9c, i-Pr) by subsequent treatment with NaI, PR(3), and NaH. The linked cycloheptatienyl-phenolate ligand in 9a could be protonated at the coordinated oxygen atom employing HBF(4).Et(2)O to yield [(HOC6H2Me2-eta7-C7H6)Mo(CO)(PPh3)]-BF4 (10). In 10, the appended phenol group is coordinated in a hemilabile fashion, which allowed the introduction of 2,6-dimethylphenyl isocyanide and CO and formation of complexes [(HOC(6)H(2)Me(2)-eta(7)-C(7)H(6))Mo(CO)(PPh(3))L]BF(4) (11, L = XyNC; 12, L = CO). On thermal reaction of [(HOC(6)H(2)Me(2)-eta(7)-C(7)H(6))Mo(CO)(2)I] (7) with dppe, the addition of the diphosphine was observed together with the simultaneous formation of the molydenum-oxygen bond to yield [(OC6H2Me2-eta3-C7H6)Mo(CO)2(dppe)] (13), in which the cycloheptatrienyl ring has reduced its hapticity from seven to three. The pseudooctahedral complex 13 exhibits an interesting fluxional behavior in solution, which has been studied by means of variable-temperature (31)P and (1)H NMR spectroscopy. A eta(3) --> eta(7) hapticity reversion could be achieved by UV irradiation of a solution of 13 in THF to give the electron-rich complex [(OC6H2Me2-eta7-C7H6)Mo(dppe)] (14). 14 was readily oxidized with ferrocenium hexafluorophosphate, and the resulting paramagnetic monocationic complex 15 has been studied by means of ESR spectroscopy and X-ray diffraction. In addition, the X-ray crystal structures of complexes 9a, 10.2CH(2)Cl(2), 12, and 13 are reported.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Matthias Tamm, Thomas Bannenberg, Bernd Dressel, Roland Fröhlich, Christiane Holst. 2002-01-14. Molybdenum complexes with linked cycloheptatrienyl-phenolate ligands.. https://doi.org/10.1021/ic010902g

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗